Two Vistagen (VTGN) directors will not seek re-election at 2026 shareholder meeting
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Vistagen Therapeutics, Inc. announced that two members of its Board of Directors, Ms. Margaret FitzPatrick and Dr. Joanne Curley, have chosen not to stand for re-election at the company’s 2026 Annual Meeting of Stockholders. Both directors will continue to serve on the board until their current terms end at the 2026 Annual Meeting. The company’s common stock continues to trade on the Nasdaq Capital Market under the symbol VTGN.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Terms
Annual Meeting of Stockholders, Nasdaq Capital Market, Emerging Growth Company
3 terms
Annual Meeting of Stockholders financial
"notified the Company of her decision not to stand for re-election at the Company’s 2026 Annual Meeting of Stockholders"
Nasdaq Capital Market financial
"Common Stock, par value $0.001 per share | VTGN | Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Emerging Growth Company regulatory
"Emerging Growth Company o"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What board changes did Vistagen Therapeutics (VTGN) disclose?
Vistagen Therapeutics disclosed that directors Margaret FitzPatrick and Joanne Curley have decided not to stand for re-election at the 2026 Annual Meeting. Both will remain on the Board until their current terms end at that meeting.
When will the Vistagen Therapeutics directors step down from the board?
Both directors will step down at the 2026 Annual Meeting of Stockholders. They will continue to serve until the end of their current terms, providing continuity of governance through that meeting before their board service concludes.
Did the Vistagen Therapeutics directors resign immediately?
No, they did not resign immediately. Margaret FitzPatrick and Joanne Curley informed the company they will not seek re-election, but will continue as directors until the conclusion of the 2026 Annual Meeting of Stockholders, when their current terms expire.
Does this Vistagen update affect the VTGN stock listing?
The update does not change the company’s listing status. Vistagen’s common stock, with a par value of $0.001 per share, continues to trade on the Nasdaq Capital Market under the ticker symbol VTGN as indicated in the disclosure.
What meeting is referenced in the Vistagen board announcement?
The announcement references Vistagen Therapeutics’ 2026 Annual Meeting of Stockholders. At that meeting, directors Margaret FitzPatrick and Joanne Curley will complete their current board terms and will not stand for re-election to continue serving afterward.